🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  2. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  3. Angiotensin (1-7)

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  4. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  5. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  6. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial

  7. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  8. Antipyrine-benzocaine otic solution

    United Therapeutics Europe Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  9. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  10. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Apheresis and Bridging Therapy

    The First People's Hospital of Lianyungang

    Large B-cell Lymphoma

    phase 2 other completed

    1 trial

  12. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  13. Aritinercept

    Aurinia Pharmaceuticals

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  14. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  15. Aspirin

    United Therapeutics Europe Ltd

    Vestibular Schwannoma

    phase 2 small molecule active

    1 trial

  16. Aspirin 75mg

    United Therapeutics Europe Ltd

    Acute Lung Injury

    phase 2 small molecule completed

    1 trial

  17. Association atezolizumab + BDB001 + RT

    Eikon Therapeutics

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  18. Atacicept

    Vera Therapeutics

    pMN

    phase 2 small molecule active

    1 trial

  19. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  20. Atacicept

    Vera Therapeutics

    IgA Nephropathy (IgAN); Berger Disease; Renal and Urinary Disorders

    phase 2 small molecule active

    1 trial

  21. Atacicept 150 mg

    Vera Therapeutics

    IgA Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  22. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Treatment of IgAN

    phase 2 small molecule active

    1 trial

  23. Atacicept Autoinjector Combination, Atacicept

    Vera Therapeutics

    Multiple Autoimmune Glomerular Diseases

    phase 2 small molecule active

    1 trial

  24. Ataluren

    PTC THERAPEUTICS, INC.

    Amino Acid Metabolism, Inborn Errors

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources